American Society of Hematology (ASH) Clinical Overview of JAK Inhibitor Therapeutics for the Management of Patients with Polycythemia Vera

American Society of Hematology (ASH) Clinical Overview of JAK Inhibitor Therapeutics for the Management of Patients with Polycythemia Vera is organized by Academic CME and will be held during Feb 09, 2017 - Feb 08, 2018.

The target audience for this medical event is Oncologists/hematologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with PV. This CME Conference has been approved for a maximum of 1.00 AMA PRA Category 1 Credits.

Conference Objectives are :
• Review the diagnostic criteria of polycythemia vera, including risk stratification and managing treatment-intolerant special patient populations.
• Analyze clinical trial data of current and emerging JAK inhibitors for the treatment of polycythemia vera presented at ASH 2016.
• Incorporate recent science to optimally address patient-specific treatment barriers to improve outcomes for patients with polycythemia vera.

Additional details will be posted as soon as they are available.